SPOTLIGHT: Dendreon faces probe

Add the SEC to the list of problems faced by Dendreon. Regulators have begun an informal investigation of the company, which has seen its stock price rise and plunge as it has struggled to gain an approval for Provenge. Analysts say the SEC wants to see if any insider trading had been going on. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.